The Zhitong Finance App learned that Fu Hong Hanlin (02696) rose nearly 4%. As of press release, it had risen 2.43% to HK$52.6, with a turnover of HK$144.374 million.

According to the news, on October 19, 2026, local time, the European Society of Medical Oncology (ESMO) annual meeting announced a research summary. Fuhong Hanlin's core product, an innovative anti-PD-1 monoclonal drug H drug Hans (Slulilizumab, European trade name Hetronifly), was selected for this conference. Among them, the US bridging ASTRIDE study will make a major appearance in the form of an oral report, as the world's first anti-PD-1 monoclonal antibody approved for first-line broad-treatment of small-cell lung cancer (ES-SCLC) as a key clinical basis for supplementing the local American population.

It is worth mentioning that as the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of widespread small-cell lung cancer, H drug has now been approved for marketing in more than 50 countries and regions, covering nearly half of the global population, and included in local health insurance payment systems in more than 10 countries. Relying on the positive data from this US bridging study, the internationalization process of H drugs is expected to accelerate, bringing more immunotherapy options to patients with solid tumors around the world.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.